Serum transforming growth factor-beta1 levels may have predictive and prognostic roles in patients with gastric cancer
Transforming growth factor-beta1 (TGF-beta1) plays an important role in the pathogenesis of multiple malignancies, and also, its expression strongly affects the outcomes of cancer patients. The objective of this study was to determine the clinical significance of the serum levels of TGF-beta1 in gas...
Gespeichert in:
| Veröffentlicht in: | Tumor biology 2015-03, Vol.36 (3), p.2097-2103 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2103 |
|---|---|
| container_issue | 3 |
| container_start_page | 2097 |
| container_title | Tumor biology |
| container_volume | 36 |
| creator | Tas, Faruk Yasasever, Ceren Tilgen Karabulut, Senem Tastekin, Didem Duranyildiz, Derya |
| description | Transforming growth factor-beta1 (TGF-beta1) plays an important role in the pathogenesis of multiple malignancies, and also, its expression strongly affects the outcomes of cancer patients. The objective of this study was to determine the clinical significance of the serum levels of TGF-beta1 in gastric cancer patients. A total of 63 patients with a pathologically confirmed diagnosis of gastric cancer were enrolled into this study. Serum TGF-beta1 concentrations were determined by the solid-phase sandwich ELISA method. Thirty healthy age- and sex-matched controls were included in the analysis. The median age at diagnosis was 62 years, range 28 to 82 years. There was no significant difference in baseline serum TGF-beta1 levels between gastric cancer patients and the healthy control group (
p
= 0.08). The known clinical variables including age of patient, gender, site of lesion, histology, histological grade, stage of disease, and serum levels of lactate dehydrogenase (LDH), CEA, and carbohydrate antigen (CA) 19.9 were not found to be correlated with serum TGF-beta1 concentrations (
p
> 0.05). However, the chemotherapy-responsive patients had higher serum TGF-beta1 levels compared with chemotherapy-unresponsive ones (median values 330.50 v 49.54 pg/mL, respectively,
p
= 0.01). Moreover, patients with elevated serum TGF-beta1 concentrations had significantly favorable overall survival compared with those with lower levels (median 71.1 v 39.9 weeks, respectively,
p
= 0.04). In conclusion, serum levels of TGF-beta1 may have predictive and prognostic roles in patients with gastric cancer. |
| doi_str_mv | 10.1007/s13277-014-2817-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1667344553</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1667344553</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-2552c44d915cbdd1dc3bb51283fbc22d183af5ed285b20082b4c7e3e804f5c463</originalsourceid><addsrcrecordid>eNp1kUuLFDEUhYMozkN_gBsJuHETzc2jK7WUwcfAgAt1HVLJrZoaqpI2SfUw_940PYoIrnLC_e7JCYeQV8DfAefd-wJSdB3joJgw0LH-CTkHJSTj0vCnTXPgTAkjz8hFKXecg-773XNyJrTsQUl-Tg7fMG8rrdnFMqa8znGiU0739ZaOzteU2YDVAV3wgEuhq3ugt-6AdJ8xzL7OTboY2jVNMZU6e5rTgoXOke5dnTHWQu_n5ja5UnMbexc95hfk2eiWgi8fz0vy49PH71df2M3Xz9dXH26YV0pUJrQWTYUetB9CgODlMGhoPxoHL0QAI92oMQijB8G5EYPyHUo0XI3aq528JG9Pvi3gzw1LtetcPC6Li5i2YmG366RSWsuGvvkHvUtbji3dkTLQshjVKDhRPqdSMo52n-fV5QcL3B5LsadSbCvFHkuxfdt5_ei8DSuGPxu_W2iAOAGljeKE-a-n_-v6Cy0MmIw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1668125584</pqid></control><display><type>article</type><title>Serum transforming growth factor-beta1 levels may have predictive and prognostic roles in patients with gastric cancer</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Tas, Faruk ; Yasasever, Ceren Tilgen ; Karabulut, Senem ; Tastekin, Didem ; Duranyildiz, Derya</creator><creatorcontrib>Tas, Faruk ; Yasasever, Ceren Tilgen ; Karabulut, Senem ; Tastekin, Didem ; Duranyildiz, Derya</creatorcontrib><description>Transforming growth factor-beta1 (TGF-beta1) plays an important role in the pathogenesis of multiple malignancies, and also, its expression strongly affects the outcomes of cancer patients. The objective of this study was to determine the clinical significance of the serum levels of TGF-beta1 in gastric cancer patients. A total of 63 patients with a pathologically confirmed diagnosis of gastric cancer were enrolled into this study. Serum TGF-beta1 concentrations were determined by the solid-phase sandwich ELISA method. Thirty healthy age- and sex-matched controls were included in the analysis. The median age at diagnosis was 62 years, range 28 to 82 years. There was no significant difference in baseline serum TGF-beta1 levels between gastric cancer patients and the healthy control group (
p
= 0.08). The known clinical variables including age of patient, gender, site of lesion, histology, histological grade, stage of disease, and serum levels of lactate dehydrogenase (LDH), CEA, and carbohydrate antigen (CA) 19.9 were not found to be correlated with serum TGF-beta1 concentrations (
p
> 0.05). However, the chemotherapy-responsive patients had higher serum TGF-beta1 levels compared with chemotherapy-unresponsive ones (median values 330.50 v 49.54 pg/mL, respectively,
p
= 0.01). Moreover, patients with elevated serum TGF-beta1 concentrations had significantly favorable overall survival compared with those with lower levels (median 71.1 v 39.9 weeks, respectively,
p
= 0.04). In conclusion, serum levels of TGF-beta1 may have predictive and prognostic roles in patients with gastric cancer.</description><identifier>ISSN: 1010-4283</identifier><identifier>EISSN: 1423-0380</identifier><identifier>DOI: 10.1007/s13277-014-2817-9</identifier><identifier>PMID: 25391430</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor - blood ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Case-Control Studies ; Female ; Gastric cancer ; Growth factors ; Humans ; Male ; Medical prognosis ; Middle Aged ; Predictive Value of Tests ; Prognosis ; Protein expression ; Research Article ; Stomach Neoplasms - blood ; Stomach Neoplasms - diagnosis ; Transforming Growth Factor beta1 - blood ; Tumorigenesis</subject><ispartof>Tumor biology, 2015-03, Vol.36 (3), p.2097-2103</ispartof><rights>International Society of Oncology and BioMarkers (ISOBM) 2014</rights><rights>International Society of Oncology and BioMarkers (ISOBM) 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-2552c44d915cbdd1dc3bb51283fbc22d183af5ed285b20082b4c7e3e804f5c463</citedby><cites>FETCH-LOGICAL-c442t-2552c44d915cbdd1dc3bb51283fbc22d183af5ed285b20082b4c7e3e804f5c463</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s13277-014-2817-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s13277-014-2817-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25391430$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tas, Faruk</creatorcontrib><creatorcontrib>Yasasever, Ceren Tilgen</creatorcontrib><creatorcontrib>Karabulut, Senem</creatorcontrib><creatorcontrib>Tastekin, Didem</creatorcontrib><creatorcontrib>Duranyildiz, Derya</creatorcontrib><title>Serum transforming growth factor-beta1 levels may have predictive and prognostic roles in patients with gastric cancer</title><title>Tumor biology</title><addtitle>Tumor Biol</addtitle><addtitle>Tumour Biol</addtitle><description>Transforming growth factor-beta1 (TGF-beta1) plays an important role in the pathogenesis of multiple malignancies, and also, its expression strongly affects the outcomes of cancer patients. The objective of this study was to determine the clinical significance of the serum levels of TGF-beta1 in gastric cancer patients. A total of 63 patients with a pathologically confirmed diagnosis of gastric cancer were enrolled into this study. Serum TGF-beta1 concentrations were determined by the solid-phase sandwich ELISA method. Thirty healthy age- and sex-matched controls were included in the analysis. The median age at diagnosis was 62 years, range 28 to 82 years. There was no significant difference in baseline serum TGF-beta1 levels between gastric cancer patients and the healthy control group (
p
= 0.08). The known clinical variables including age of patient, gender, site of lesion, histology, histological grade, stage of disease, and serum levels of lactate dehydrogenase (LDH), CEA, and carbohydrate antigen (CA) 19.9 were not found to be correlated with serum TGF-beta1 concentrations (
p
> 0.05). However, the chemotherapy-responsive patients had higher serum TGF-beta1 levels compared with chemotherapy-unresponsive ones (median values 330.50 v 49.54 pg/mL, respectively,
p
= 0.01). Moreover, patients with elevated serum TGF-beta1 concentrations had significantly favorable overall survival compared with those with lower levels (median 71.1 v 39.9 weeks, respectively,
p
= 0.04). In conclusion, serum levels of TGF-beta1 may have predictive and prognostic roles in patients with gastric cancer.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Case-Control Studies</subject><subject>Female</subject><subject>Gastric cancer</subject><subject>Growth factors</subject><subject>Humans</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Protein expression</subject><subject>Research Article</subject><subject>Stomach Neoplasms - blood</subject><subject>Stomach Neoplasms - diagnosis</subject><subject>Transforming Growth Factor beta1 - blood</subject><subject>Tumorigenesis</subject><issn>1010-4283</issn><issn>1423-0380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kUuLFDEUhYMozkN_gBsJuHETzc2jK7WUwcfAgAt1HVLJrZoaqpI2SfUw_940PYoIrnLC_e7JCYeQV8DfAefd-wJSdB3joJgw0LH-CTkHJSTj0vCnTXPgTAkjz8hFKXecg-773XNyJrTsQUl-Tg7fMG8rrdnFMqa8znGiU0739ZaOzteU2YDVAV3wgEuhq3ugt-6AdJ8xzL7OTboY2jVNMZU6e5rTgoXOke5dnTHWQu_n5ja5UnMbexc95hfk2eiWgi8fz0vy49PH71df2M3Xz9dXH26YV0pUJrQWTYUetB9CgODlMGhoPxoHL0QAI92oMQijB8G5EYPyHUo0XI3aq528JG9Pvi3gzw1LtetcPC6Li5i2YmG366RSWsuGvvkHvUtbji3dkTLQshjVKDhRPqdSMo52n-fV5QcL3B5LsadSbCvFHkuxfdt5_ei8DSuGPxu_W2iAOAGljeKE-a-n_-v6Cy0MmIw</recordid><startdate>20150301</startdate><enddate>20150301</enddate><creator>Tas, Faruk</creator><creator>Yasasever, Ceren Tilgen</creator><creator>Karabulut, Senem</creator><creator>Tastekin, Didem</creator><creator>Duranyildiz, Derya</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20150301</creationdate><title>Serum transforming growth factor-beta1 levels may have predictive and prognostic roles in patients with gastric cancer</title><author>Tas, Faruk ; Yasasever, Ceren Tilgen ; Karabulut, Senem ; Tastekin, Didem ; Duranyildiz, Derya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-2552c44d915cbdd1dc3bb51283fbc22d183af5ed285b20082b4c7e3e804f5c463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Case-Control Studies</topic><topic>Female</topic><topic>Gastric cancer</topic><topic>Growth factors</topic><topic>Humans</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Protein expression</topic><topic>Research Article</topic><topic>Stomach Neoplasms - blood</topic><topic>Stomach Neoplasms - diagnosis</topic><topic>Transforming Growth Factor beta1 - blood</topic><topic>Tumorigenesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tas, Faruk</creatorcontrib><creatorcontrib>Yasasever, Ceren Tilgen</creatorcontrib><creatorcontrib>Karabulut, Senem</creatorcontrib><creatorcontrib>Tastekin, Didem</creatorcontrib><creatorcontrib>Duranyildiz, Derya</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Tumor biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tas, Faruk</au><au>Yasasever, Ceren Tilgen</au><au>Karabulut, Senem</au><au>Tastekin, Didem</au><au>Duranyildiz, Derya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum transforming growth factor-beta1 levels may have predictive and prognostic roles in patients with gastric cancer</atitle><jtitle>Tumor biology</jtitle><stitle>Tumor Biol</stitle><addtitle>Tumour Biol</addtitle><date>2015-03-01</date><risdate>2015</risdate><volume>36</volume><issue>3</issue><spage>2097</spage><epage>2103</epage><pages>2097-2103</pages><issn>1010-4283</issn><eissn>1423-0380</eissn><abstract>Transforming growth factor-beta1 (TGF-beta1) plays an important role in the pathogenesis of multiple malignancies, and also, its expression strongly affects the outcomes of cancer patients. The objective of this study was to determine the clinical significance of the serum levels of TGF-beta1 in gastric cancer patients. A total of 63 patients with a pathologically confirmed diagnosis of gastric cancer were enrolled into this study. Serum TGF-beta1 concentrations were determined by the solid-phase sandwich ELISA method. Thirty healthy age- and sex-matched controls were included in the analysis. The median age at diagnosis was 62 years, range 28 to 82 years. There was no significant difference in baseline serum TGF-beta1 levels between gastric cancer patients and the healthy control group (
p
= 0.08). The known clinical variables including age of patient, gender, site of lesion, histology, histological grade, stage of disease, and serum levels of lactate dehydrogenase (LDH), CEA, and carbohydrate antigen (CA) 19.9 were not found to be correlated with serum TGF-beta1 concentrations (
p
> 0.05). However, the chemotherapy-responsive patients had higher serum TGF-beta1 levels compared with chemotherapy-unresponsive ones (median values 330.50 v 49.54 pg/mL, respectively,
p
= 0.01). Moreover, patients with elevated serum TGF-beta1 concentrations had significantly favorable overall survival compared with those with lower levels (median 71.1 v 39.9 weeks, respectively,
p
= 0.04). In conclusion, serum levels of TGF-beta1 may have predictive and prognostic roles in patients with gastric cancer.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>25391430</pmid><doi>10.1007/s13277-014-2817-9</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1010-4283 |
| ispartof | Tumor biology, 2015-03, Vol.36 (3), p.2097-2103 |
| issn | 1010-4283 1423-0380 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1667344553 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adult Aged Aged, 80 and over Biomarkers, Tumor - blood Biomedical and Life Sciences Biomedicine Cancer Research Case-Control Studies Female Gastric cancer Growth factors Humans Male Medical prognosis Middle Aged Predictive Value of Tests Prognosis Protein expression Research Article Stomach Neoplasms - blood Stomach Neoplasms - diagnosis Transforming Growth Factor beta1 - blood Tumorigenesis |
| title | Serum transforming growth factor-beta1 levels may have predictive and prognostic roles in patients with gastric cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T07%3A54%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20transforming%20growth%20factor-beta1%20levels%20may%20have%20predictive%20and%20prognostic%20roles%20in%20patients%20with%20gastric%20cancer&rft.jtitle=Tumor%20biology&rft.au=Tas,%20Faruk&rft.date=2015-03-01&rft.volume=36&rft.issue=3&rft.spage=2097&rft.epage=2103&rft.pages=2097-2103&rft.issn=1010-4283&rft.eissn=1423-0380&rft_id=info:doi/10.1007/s13277-014-2817-9&rft_dat=%3Cproquest_cross%3E1667344553%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1668125584&rft_id=info:pmid/25391430&rfr_iscdi=true |